Abstract
We assessed the long-term safety, effectiveness and quality of a fixed-dose combination of nevirapine, stavudine and lamivudine (triomune). HIV-1-infected adults initially enrolled in a one-year, open-label, single-arm, multicentre trial in Cameroon were followed for 2 years. Our results support the safety and effectiveness of the triomune combination for first-line treatment of HIV infection. Virological effectiveness appeared to wane somewhat during the second year of treatment, however, and plasma nevirapine concentrations were relatively high.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / therapeutic use*
-
CD4 Lymphocyte Count
-
Drug Resistance, Viral
-
Drug Therapy, Combination
-
Female
-
Humans
-
Lamivudine / adverse effects
-
Lamivudine / blood
-
Lamivudine / therapeutic use*
-
Long-Term Care / methods
-
Male
-
Nevirapine / adverse effects
-
Nevirapine / blood
-
Nevirapine / therapeutic use*
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Stavudine / adverse effects
-
Stavudine / blood
-
Stavudine / therapeutic use*
-
Treatment Outcome
-
Viral Load
Substances
-
Anti-HIV Agents
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
Nevirapine
-
Stavudine